Is your age greater than or equal to 12 yrs?
Are you female?
Do you have any of these conditions: Urinary tract infection or Bacterial Infection or Urinary Tract Infections or Bacterial Infections?
Do you have any of these conditions: Bacterial Infection or Urinary tract infection or Recurrent Urinary Tract Infection or urinary infection or Urinary Tract Infections or Bacterial Infe...?
Do you have any of these conditions: Recurrent Urinary Tract Infection or Bacterial Infections or Recurrent Urinary Tract Infections or urinary tract infection (uti) or recurrent utis or ...?
Do you have any of these conditions: Recurrent Urinary Tract Infections or Urinary tract infection or urinary infection or urinary tract infection (uti) or recurrent utis or Bacterial Inf...?
Do you have any of these conditions: urinary tract infection (uti) or Urinary tract infection or Bacterial Infection or urinary infection or Urinary Tract Infections or Recurrent Urinary ...?
Do you have any of these conditions: Bacterial Infection or Recurrent Urinary Tract Infection or Urinary Tract Infections or Recurrent Urinary Tract Infections or urinary tract infection ...?
The participant is >=12 years of age at the time of signing the informed consent/assent and has a body weight >=40 kilogram (kg)
The participant has 2 or more of the following clinical signs and symptoms of acute cystitis with onset <=72 hours prior to study entry: dysuria, frequency, urgency, or lower abdominal pain
The participant has nitrite or pyuria (>15 white blood cell [WBC]/high-power field [HPF]) or the presence of 3 plus (+)/large leukocyte esterase) from a pretreatment clean-catch midstream urine sample based on local laboratory procedures
The participant is female
Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
A female participant is eligible to participate if she is a woman of childbearing potential (WOCBP) who is not pregnant as confirmed by a high sensitivity urine pregnancy test at Baseline (Day 1) regardless of current or prior contraception use or abstinence, is not breastfeeding, or is not a WOCBP
Additional requirements for pregnancy testing during and after study intervention are specified
The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy
The participant is capable of giving signed informed consent/assent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF)/assent form and protocol
The participant resides in a nursing home or dependent care type-facility
The participant has a body mass index >=40.0 kilogram per meter square (kg/m^2) or a body mass index >=35.0 kg/m^2 and is experiencing obesity-related health conditions such as high blood pressure or uncontrolled diabetes
The participant has a history of sensitivity to the study interventions, or components thereof, or a history of a drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates her participation
The participant is immunocompromised or has altered immune defenses that may predispose the participant to a higher risk of treatment failure and/or complications (e.g., uncontrolled diabetes, renal transplant recipients, participants with clinically significant persistent granulocytopenia [absolute neutrophil count <1000/microliter (L)], and participants receiving immunosuppressive therapy, including corticosteroid therapy [>40 milligrams (mg)/day prednisolone or equivalent for >1 week, >=20 mg/day prednisolone or equivalent for >2 weeks, or prednisolone or equivalent >=10 mg/day for >6 weeks]). Participants with a known cluster of differentiation 4 (CD4) count of <200 cells per cubic millimeter (cells/mm^3) should not be enrolled
The participant has any of the following: Medical condition that requires medication that may be impacted by inhibition of acetylcholinesterase, such as
Medical condition that requires medication that may be impacted by inhibition of acetylcholinesterase, such as
Poorly controlled asthma or chronic obstructive pulmonary disease at Baseline and, in the opinion of the investigator, not stable on current therapy
Acute severe pain, uncontrolled with conventional medical management
Active peptic ulcer disease
A history of seizure disorder requiring medications for control (this does not include a history of childhood febrile seizures) or
Any surgical or medical condition (active or chronic) that may interfere with drug absorption, distribution, metabolism, or excretion of the study intervention (e.g., ileostomy or malabsorption syndrome)
The participant has a known glucose-6 phosphate dehydrogenase deficiency
The participant has a serious underlying disease that could be imminently life threatening, or the participant is unlikely to survive for the duration of the study period
The participant has acute cystitis that is known or suspected to be due to fungal, parasitic, or viral pathogens; or known or suspected to be due to Pseudomonas aeruginosa or Enterobacteriaceae (other than Escherichia coli) as the contributing pathogen
The participant has symptoms known or suspected to be caused by another disease process, such as asymptomatic bacteriuria, overactive bladder, chronic incontinence, or chronic interstitial cystitis, that may interfere with the clinical efficacy assessments
The participant has an anatomical or physiological anomaly that predisposes the participant to UTIs or may be a source of persistent bacterial colonization, including calculi, obstruction or stricture of the urinary tract, primary renal disease (e.g., polycystic renal disease), or neurogenic bladder, or the participant has a history of anatomical or functional abnormalities of the urinary tract (e.g., chronic vesico-ureteral reflux, detrusor insufficiency)
The participant has an indwelling catheter, nephrostomy, ureter stent, or other foreign material in the urinary tract
The participant who, in the opinion of the investigator, has an otherwise complicated UTI, an active upper UTI (e.g., pyelonephritis, urosepsis), signs and symptom onset >=96 hours before study entry, or a temperature >=101 degree Fahrenheit, flank pain, chills, or any other manifestations suggestive of upper UTI
The participant has known anuria, oliguria, or significant impairment of renal function (creatinine clearance <60 milliliters per minute (mL/min) or clinically significant elevated serum creatinine as determined by the investigator)
The participant presents with vaginal discharge at Baseline (e.g., suspected sexually transmitted disease)
The participant has congenital long QT syndrome or known prolongation of the QTc interval
The participant has uncompensated heart failure
The participant has severe left ventricular hypertrophy
The participant has a family history of QT prolongation or sudden death
The participant has a recent history of vasovagal syncope or episodes of symptomatic bradycardia or brady arrhythmia within the last 12 months
The participant is taking QT-prolonging drugs or drugs known to increase the risk of torsades de pointes (TdP) per the [www.crediblemeds.org](http://www.crediblemeds.org/). "Known Risk of TdP" category at the time of her Baseline Visit, which cannot be safely discontinued from the Baseline Visit to the TOC Visit; or the participant is taking a strong cytochrome P450 enzyme 3A4 (CYP3A4) inhibitor or a strong P-glycoprotein (P-gp) inhibitor
For any participant >=12 to <18 years of age, the participant has an abnormal ECG reading at Baseline or during the study intervention
The participant has a QTc >450 msec or a QTc >480 msec for participants with bundle-branch block
The participant has a documented or recent history of uncorrected hypokalemia within the past 3 months
The participant has a known ALT value >2 upper limit of normal (ULN)
The participant has a known bilirubin value >1.5 ULN (isolated bilirubin >1.5 ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)
The participant has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice
The participant has a previous history of cholestatic jaundice/hepatic dysfunction associated with nitrofurantoin
The participant has received treatment with other systemic antimicrobials or systemic antifungals within 1 week before study entry
The participant must agree not to use the medications or nondrug therapies from the Baseline Visit through the TOC Visit
The participant has been previously enrolled in this study or has previously been treated with gepotidacin
The participant has participated in a clinical trial and has received an investigational product within 30 days or 5 half-lives, whichever is longer